Monoclonal Antibody to Receptor Activator Of Nuclear Factor Kappa B Ligand (RANkL)
Code | Size | Price |
---|
MAA855Ra22-20ul | 20uL | £89.00 |
Quantity:
MAA855Ra22-100ul | 100ul | £168.00 |
Quantity:
MAA855Ra22-200ul | 200ul | £226.00 |
Quantity:
MAA855Ra22-1ml | 1ml | £519.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG2a Kappa
Antibody Clonality: Monoclonal
Antibody Clone: C5
Regulatory Status: RUO
Target Species: Rat
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CD254; TNFSF11; ODF; OPGL; TRANCE; HRANKL2; SOdf; Tumor Necrosis Factor(ligand)superfamily Member 11; TNF-related activation-induced cytokine
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Receptor Activator Of Nuclear Factor Kappa B Ligand
Potency (Clone Number):
C5
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Receptor Activator Of Nuclear Factor Kappa B Ligand (RANkL) | RPA855Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||